Big compounders will have until May 22 to stop producing and dispensing compounded semaglutide, while smaller, state-run ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according ...

SUSTAIN-6 documented absolute rates of 3.0% for retinopathy complications with semaglutide versus 1.8% with placebo. This discrepancy between the current post-marketing findings and prior clinical ...

"With the FDA announcing the resolution of shortages for Semaglutide (Wegovy, Ozempic) and Tirzepatide (Zepbound, Mounjaro), compounding pharmacies must halt production of these medications. This ...